Optimal Duration of Treatment With Eculizumab in Atypical Hemolytic Uremic Syndrome (aHUS)—a Question to Be Addressed in a Scientific Way

Pediatric Nephrology - Germany
doi 10.1007/s00467-019-4192-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC